Literature DB >> 18318779

Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis.

I M Hamour1, H J Lachmann, H J B Goodman, M Petrou, M M Burke, P N Hawkins, N R Banner.   

Abstract

Heart failure is the usual cause of death in patients with amyloid cardiomyopathy. The commonest form of hereditary cardiac amyloidosis is associated with the Val122Ile variant of transthyretin (TTR), which is carried by 3-4% of the African American population. Here, we report the outcome of the first cardiac transplantation in a patient with TTR V122I. A 59-year-old Caribbean man presented with biventricular failure. Other than previous bilateral carpel tunnel syndrome, he had been well and had no evidence of extracardiac amyloidosis. An endomyocardial biopsy demonstrated amyloid of TTR type. Sequencing of TTR gene indicated homozygosity for V122I. He underwent cardiac transplantation and 3 years later, remains well with no evidence of allograft or systemic amyloid deposition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18318779     DOI: 10.1111/j.1600-6143.2008.02162.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  14 in total

1.  Restrictive cardiomyopathy in inherited ATTR amyloidosis (TTR-Ser23Asn) in a patient of German-Italian extraction.

Authors:  Iris I Mueller; Meinrad Gawaz; Reinhold P Linke; Christine Zuern; Dagmar Steiner; Klaus Altland; Nicolas Von Beckerath; Hans-Joerg Weig
Journal:  BMJ Case Rep       Date:  2010-03-08

Review 2.  A new era in clinical genetic testing for hypertrophic cardiomyopathy.

Authors:  Matthew Wheeler; Aleksandra Pavlovic; Emil DeGoma; Heidi Salisbury; Colleen Brown; Euan A Ashley
Journal:  J Cardiovasc Transl Res       Date:  2009-10-30       Impact factor: 4.132

3.  Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity.

Authors:  Mamoun M Alhamadsheh; Stephen Connelly; Ahryon Cho; Natàlia Reixach; Evan T Powers; Dorothy W Pan; Ian A Wilson; Jeffery W Kelly; Isabella A Graef
Journal:  Sci Transl Med       Date:  2011-08-24       Impact factor: 17.956

Review 4.  Emerging Advances in the Management of Cardiac Amyloidosis.

Authors:  Michael N Vranian; Brett W Sperry; Jason Valent; Mazen Hanna
Journal:  Curr Cardiol Rep       Date:  2015-11       Impact factor: 2.931

5.  Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.

Authors:  Steve Bourgault; Sungwook Choi; Joel N Buxbaum; Jeffery W Kelly; Joshua L Price; Natàlia Reixach
Journal:  Biochem Biophys Res Commun       Date:  2011-05-04       Impact factor: 3.575

6.  Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation.

Authors:  Ashutosh D Wechalekar; Mark Offer; Julian D Gillmore; Philip N Hawkins; Helen J Lachmann
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-12-17

Review 7.  Novel drugs targeting transthyretin amyloidosis.

Authors:  Mazen Hanna
Journal:  Curr Heart Fail Rep       Date:  2014-03

8.  AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.

Authors:  Sravan C Penchala; Stephen Connelly; Yu Wang; Miki S Park; Lei Zhao; Aleksandra Baranczak; Irit Rappley; Hannes Vogel; Michaela Liedtke; Ronald M Witteles; Evan T Powers; Natàlia Reixach; William K Chan; Ian A Wilson; Jeffery W Kelly; Isabella A Graef; Mamoun M Alhamadsheh
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

Review 9.  Heart transplantation in cardiac amyloidosis.

Authors:  Matthew Sousa; Gregory Monohan; Navin Rajagopalan; Alla Grigorian; Maya Guglin
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

Review 10.  Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans.

Authors:  Joel N Buxbaum; Frederick L Ruberg
Journal:  Genet Med       Date:  2017-01-19       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.